Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 3/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937011 | 0.86 | LMNA (0.58) | LMNAHPGDALDH1A1MAOBMAOA | |
| SCHEMBL11930610 | 0.86 | LMNA (0.58) | LMNAHPGDALDH1A1MAOBMAOA | |
| SCHEMBL16716377 | 0.85 | LMNA (0.59) | LMNAHPGDALDH1A1MAOBMAOA | |
| SCHEMBL1033009 | 0.82 | LMNA (0.64) | LMNAHPGDALDH1A1MAOBMAOA | |
| SCHEMBL22849991 | 0.81 | SMN1; SMN2 (0.59) | LMNAHPGDALDH1A1NPC1RAB9A | |
| SCHEMBL26962766 | 0.81 | LMNA (0.73) | LMNAHPGDALDH1A1MAOBMAOA | |
| SCHEMBL22849990 | 0.76 | DYRK1A (0.63) | LMNAHPGDALDH1A1NPC1RAB9A | |
| SCHEMBL14959514 | 0.75 | MAPT (0.67) | LMNAHPGDALDH1A1MAOBNPC1 | |
| SCHEMBL30563071 | 0.74 | RAB9A (0.57) | LMNAHPGDALDH1A1NPC1RAB9A | |
| SCHEMBL26962730 | 0.74 | RAB9A (0.57) | LMNAHPGDALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | LMNA 4145/4885HPGD 792/4885ALDH1A1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.